Programs in Development:

Broad-based pipeline of unique acute and chronic care pharmacologic programs


Critical care and underserved acute and chronic medical conditions


Stephen J. Petti, CEO
Laurence M. Katz, MD, CSO
Ron Tribble, DMD, Sr Bus Advisor
Melisa Barron, PhD., CMC
Sydney Gilman, PhD., RA
Kathryn Martin, PharmD, DD
Samn Raffaniello, Proj Svcs
Patricia Pierce, Admin Asst

Hibernaid is a privately held company developing unique drugs for important acute medical indications in high-risk critical care patient populations, as well as unique treatments targeting underserved chronic indications.

The Company's lead development compound is HBN-1, a unique intravenous combination drug that pharmaceutically induces clinically-relevant regulated hypothermia or temperature management (deliberate reduction of core body temperature) to prevent neurological, functional and organ damage and significantly increase the probability of survival in a broad range of acute care medical conditions.

HBN-1 is initially being developed for use in resuscitated post-cardiac arrest patients but the technology will also be developed for the treatment of stroke, traumatic brain injury, spinal cord injury and other acute critical care indications, as well as sepsis and organ transplant.

The Company is also developing important new drugs to treat a variety of medical indications, most notably mild concussion (including sports related injuries), Progeria, an orphan indication that causes premature aging and early death in children, menopausal-related 'hot flashes', and symptomatic treatment of effects associated with Multiple Sclerosis (MS), Duchenne Muscular Dystrophy (DMD) and other conditions associated with muscular weakness caused by overheating.

Hibernaid, Inc. image 1 Hibernaid in the News
Questions? Click here to contact us.
Hibernaid, Inc. image 2